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Context:Evidence-based strategies topreventprogressionofdysglycemia innewlydiagnosed type
2 diabetes are needed.
Objective: To undertake a secondary analysis of the Early Diabetes Intervention Program (EDIP) in
order to understand the features that were protective against worsening glycemia.
Design: EDIP was a randomized, placebo-controlled trial.
Setting: Two university diabetes centers.
Patients: A total of 219 overweight individuals with fasting glucose 7.8 mmol/L and 2-hour oral
glucose tolerance test (OGTT) glucose  11.1 mmol/L.
Interventions:Acarbose versus placebo, on a background of dietary recommendations, with quar-
terly visits to assess glycemia and intervention adherence for up to 5 years.
Main Outcome Measures: Progression of fasting glucose  7.8 mmol/L on two consecutive quar-
terly visits. Cox proportional hazards modeling and ANOVA were performed to evaluate deter-
minants of progression.
Results:Progression-freestatuswasassociatedwithreductions inweight,fastingglucose,2-hourOGTT
glucose, and increases in the high-density lipoprotein/triglyceride ratio. The reduction in fasting glu-
cose was the only effect that remained significantly associated with progression-free status in multi-
variable Cox modeling. The reduction in fasting glucose was in turn primarily associated with reduc-
tions in weight and in 2-hour OGTT glucose. Acarbose treatment did not explain these changes.
Conclusions: In early diabetes, reductions in glucose, driven by reductions in weight, can delay
progressivemetabolic worsening. These observations underscore the importance of lifestyleman-
agement including weight loss as a tool to mitigate worsening of glycemia in newly diagnosed
diabetes. (J Clin Endocrinol Metab 101: 4076–4084, 2016)
The Early Diabetes Intervention Program (EDIP) was arandomized, placebo-controlled, clinical trial evalu-
ating the effect of acarbose vs placebo on a background of
lifestyle recommendations to delay the progressionof fast-
ing plasma glucose (FPG) in a population with screen-
detected, early diabetes. The primary analysis of EDIP has
been previously published; there was no statistical differ-
ence between treatment groups in the cumulative inci-
dence of progression of fasting glucose above a threshold
of 7.8 mmol/L (140 mg/dL) over the 5-year period of ob-
servation (1). We have also previously published findings
that this population exhibited surprisingly poor -cell
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function overall, despite their very early, screen-detected
diabetes, and there was surprisingly little effect of the
study interventions to improve -cell function (2), despite
reductions in glucose.
Nevertheless, the study population exhibited a range of
responses to study interventions, including reductions in
glucose and weight, in relation to differences in progres-
sion. Understanding the relationships of these changes in
metabolic physiology to disease progression can improve
our understanding of the physiology of progression and
help us to better identify targets for protection against
progression in early diabetes. With this goal in mind, we
have undertaken post hoc analyses of the EDIP data to
formally evaluate the determinants of progression and, by
corollary, protection from progression in EDIP.
Subjects and Methods
The study was approved by the institutional review boards of
Indiana University School of Medicine andWashington Univer-
sity School of Medicine, and all subjects provided written in-
formed consent for the research. Inclusion and exclusion criteria
and general methods for the EDIP trial have been previously
published (1). Participants were recruited from the surrounding
communities using a process that included oral glucose tolerance
test (OGTT) screening of asymptomatic individuals without
known diabetes. To qualify for the EDIP, volunteers had to have
2-hour 75-g OGTT readings  11.1 but fasting glucose  7.8
mmol/L. The latter was the diagnostic cut-point for diabetes at
the time the trial began. Subjects were randomly assigned to
either acarbose or an identical placebo. Study drug administra-
tion was initiated at a dose of 25 mg once daily with the evening
meal, then titrated at weekly intervals by 25 mg daily to the
maximum dose of 100 mg three times daily with meals. Study
dosing was reduced as needed in subjects who complained of
gastrointestinal side effects. Efforts were made to reach a daily
dosage of at least 50 mg three times daily of acarbose or equiv-
alent placebo tablets. At baseline, participants met with a study
dietitian and were provided with recommendations for a diet
appropriate for type 2 diabetes, including carbohydrate and cal-
orie restriction and identifying targets for these components, but
not identifying a specific weight loss target. At each quarterly
visit, participants were weighed and asked to provide diet recall
records.
The study definition of progression was met by achieving a
fasting glucose value7.8mmol/Lon two consecutive quarterly
visits.
Study measurements
At study baseline, anthropomorphic and metabolic parame-
ters were measured, and a 75-g oral glucose tolerance test
(OGTT)was performed.Weight and height weremeasuredwith
participants wearing light clothing, and body mass index was
calculated as weight divided by the square of the height (kg/m2).
Bloodpressurewasmeasured in the right armwhile subjectswere
seated using an automated blood pressure cuff (Dinamap, Cri-
tikon; GE Healthcare). This testing was repeated at yearly visits
for the duration of observation, up to a maximum of 5 years.
Study treatment was withheld the morning of the OGTT. Sub-
jects returned quarterly for medication dispensing and blood
sampling, including fasting glucose measurements. If subjects
met the primary endpoint of the study (ie, progression of fasting
glucose) at quarterly or annual visits, their participation was
terminated, and no further metabolic measurements were
obtained.
Assessment of treatment adherence
At quarterly study visits, previously dispensed medications
were collected, and fresh bottles were provided. Medication ad-
herence was calculated as the percentage of prescribed medica-
tion that was missing from returned bottles. Participants were
deemed compliant if at least 80% of the prescribed medications
were taken in the interval.
Asnotedabove, adherencewith thedietary recommendations
was assessed at quarterly visits by measuring body weight and
through food records thatwere reviewedwith the studydietitian.
Assays
Glucose concentrations were determined using a glucose ox-
idase method (YSI). Hemoglobin A1c (HbA1c) was measured
using an immunoturbidimetric assay (RocheDiagnostics). Total
andhigh-density lipoprotein (HDL) cholesterol and triglycerides
(TGs) weremeasured using an enzymatic endpoint assay (Roche
Diagnostics). Low-density lipoprotein cholesterol concentration
was derived using the Friedewald calculation if the value for TGs
was  400 mg/dL (4.5 mmol/L). Insulin and proinsulin were
measured byRIA (LincoResearch), with fasting values being the
mean of 30- and 0-minute samples. Nonesterified fatty acids
were measured using a colorimetric method (Wako). All labo-
ratory assays for both sites, other than the YSI plasma glucose
measurements, were done at the central study laboratory at the
Indiana University School of Medicine.
Calculations
Fasting insulin values consisted of the average of the two
baseline values measured at the time of OGTT procedures.
-Cell function was assessed using OGTT data as the insulino-
genic index [(30 minute  fasting insulin [U/mL])  (30 min-
ute fasting glucose [mg/dL])], reflecting theOGTTearly-phase
insulin response, and the insulin area under the curve (calculated
using the trapezoidal rule), reflecting the OGTT late-phase in-
sulin response. Insulin sensitivity was estimated using inverse
fasting insulin, combined with concurrent glucose readings into
a homeostasis model assessment of insulin resistance (HOMA-
IR) calculation or combined with the insulinogenic index from
the OGTT to derive an oral disposition index (2, 3). Where this
calculation produced negative values (a numerically possible but
physiologically impossible result), those were set to missing for
purposes of statistical analyses.
Statistical analysis
Two sets of analyses were undertaken. First, we evaluated
anthropomorphic andmetabolic determinants of progression of
fasting glucose, combining subjects receiving the drug or placebo
because there was no effect of drug. These analyses applied Cox
proportional hazards modeling to the time-to-progression data,
evaluating variables individually and then inmultivariablemod-
els. The parameters of interest included measures of weight and
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metabolic status and explicitly included measures of insulin re-
sistance and-cell function. Themaximal treatment effects were
apparent after the first year of observation, and owing to the
study design, this time point also provided the maximal number
of evaluable participants in the follow-up interval. Therefore,we
evaluated the baseline and 1-year change in the variables of in-
terest. We also undertook evaluations using the post-baseline
time-dependent change in the variables of interest to evaluate all
available data in relation to progression events. Multivariable
models were constructed using all variables that exhibited uni-
variate associations with P  .20; separate models were con-
structed including year 1 change variables or time-dependent
change variables. These analyses revealed that the change in fast-
ing glucose was a potent determinant of progression, even after
adjustment for the potent effect of initial fasting glucose. There-
fore, a second set of analyses was undertaken to explore in detail
the factors that contributed to this change in fasting glucose,
using a parallel approach of identifying univariate associations
and then performingmultivariable analyses. SPSS software (ver-
sion 20; IBM) was used to perform all statistical analyses. Two-
sided P values .05 were considered statistically significant for
all comparisons, with no adjustment for multiple testing. Signif-
icance results near this threshold (.01  P  .05) are described
in the text as having “borderline” significance in view of the
exploratory nature of these observations to guard against
overinterpretation.
Results
Thecharacteristics ofparticipants at study entryhavebeen
previously reported (1). Table 1 presents demographic
characteristics comparing the group who progressed to
those who did not progress during the 5 years of obser-
vation.These groupsdidnotdiffer byage, sex, race, family
history of diabetes, or history of prior gestational diabetes
among the female participants. Evaluating non-progres-
sor vs progressor group differences in metabolic variables
(Table 2; non-progressor vs progressor within baseline
data), the principal difference was in a lower fasting glu-
cose at study entry among those who did not progress
(6.54 mmol/L) compared to those who did progress (7.19
mmol/L). After the first year of study intervention, there
were reductions in weight, fasting glucose, and 2-hour
glucose after 75-g OGTT (Table 2; baseline vs year 1).
Specifically, progressors exhibited smaller reductions in
Table 1. Baseline Demographic Characteristics of the
Population
Baseline
Characteristics
Non-
Progressors Progressors P Value
n 134 62
Age (mean  SD), y 54.9  11.4 52.6  11.5 .16
Gender .12
Male 41 (30.6) 26 (41.9)
Female 93 (69.4) 36 (58.1)
Race .49
Caucasian 101 (75.4) 51 (82.3)
African American 24 (17.9) 11 (17.7)
Other 9 (6.7) 0 (0)
Family history of
diabetes mellitus
.70
Yes 89 (66.4) 43 (70.5)
No 37 (27.6) 16 (26.2)
Unknown 8 (6.0) 2 (3.3)
Randomized treatment .37
Acarbose 82 (74.5) 28 (25.5)
Placebo 75 (68.8) 34 (31.2)
Data are expressed as number (percentage), unless stated otherwise.
Note: This is a comparison of epidemiological characteristics and
randomized treatments in progressor/non-progressor subgroups of the
EDIP study population. Progression status is defined using the main
study definition of progression of FPG as described in the Subjects and
Methods. P values are from 2 analysis for categorical variables.
Table 2. Metabolic Characteristics of Progressors vs Non-Progressors at Baseline and After 1 Year of Study
Intervention
Baseline Year 1 P Value
Non-
Progressors Progressors P Value
Non-
Progressors Progressors P Value
Progression
Group Effect
On-Treatment
Effect
Progression-
Treatment Interaction
n 134 62 108 56
Weight, kg 97.3  21.0 102.4  21.2 .11 91.7  19.1 98.9  22.0 .032 .034 .0001 .74
FPG, mmol/L 6.54  0.77 7.19  0.51 .0001 6.0  0.8 7.1  0.9 .0001 .0001 .0001 .008
OGTT 120-min glucose, mmol/L 13.02  1.58 13.28  2.03 .37 11.30  2.59 12.07  2.80 .07 .06 .0001 .28
HbA1c, % 6.33  0.65 6.38  0.57 .55 6.11  0.66 6.39  0.68 .01 .02 .39 .14
HOMA-IR, U 5.91  4.29 6.76  3.91 .19 5.25  4.89 7.06  5.83 .06 .014 .88 .86
Disposition index 4.75  8.88 3.91  4.58 .49 2.61  4.24 2.86  3.93 .74 .94 .008 .90
Fasting proinsulin, pmol/L 23.8  21.7 22.7  13.9 .77 18.2  11.1 26.2  20.0 .02 .015 .38 .64
Fasting insulin, pmol/L 146.6  98.5 152.3  93.1 .52 137.2  116.2 158.8  138.8 .34 .0001 .0001 .008
Fasting NEFA, mmol/L 574.8  187.3 578.0  190.9 .59 491.6  167.8 517.1  153.1 .76 .27 .001 .93
Total cholesterol, mmol/L 5.13  1.04 5.17  0.99 .83 4.97  0.84 4.96  1.02 .91 .68 .007 .56
HDL cholesterol, mmol/L 1.02  0.22 0.96  0.26 .09 1.05  0.24 1.02  0.26 .43 .15 .001 .24
LDL cholesterol, mmol/L 4.15  0.98 4.04  1.02 .50 4.10  0.73 3.87  0.95 .10 .31 .13 .36
TG, mmol/L 2.11  1.10 2.65  1.30 .10 1.88  0.94 2.58  1.10 .007 .009 .017 .59
HDL/TG ratio, mmol/L 0.11  0.06 0.09  0.09 .05 0.13  0.08 0.10  0.11 .01 .009 .001 .31
Abbreviations: LDL, low-density lipoprotein; NEFA, non-esterified fatty acids. Note: This is a comparison of metabolic parameters in progressor/
non-progressor subgroups of the EDIP study population. Progression status is defined using the main study definition of progression of FPG as
described in Subjects and Methods. P values are from ANOVA (comparisons within each year) or repeated measures ANOVA comparing overall
differences by group, time, and the interaction of these terms.
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fasting glucose (0.1 mmol/L) than non-progressors (0.5
mmol/L; P .008 comparing this change), whereas both
groups experienced similar reductions in 2-hour OGTT
glucose (1.7 vs 1.3 mmol/L reductions; P .0001 for the
reduction, and P  .28 comparing this effect between
groups) and similar reductions in weight (5 vs 3 kg reduc-
tions; P .0001 for the reduction and P .74 comparing
this effect between groups; Table 2). These changes were
accompanied by reductions in concentrations of fasting
insulin, nonesterified fatty acids, HDL cholesterol, TGs,
and the HDL/TG ratio, all concordant with the reduction
inweight and improved insulin resistance.-Cell function
was reduceddespite this improvement in insulin resistance
(Table 2). The progressors differed from non-progressors
in these on-study effects in fasting glucose and fasting in-
sulin (Table 2; non-progressor vs
progressor by baseline vs year 1).
The relationships of these param-
eters with time to progression were
evaluated by dividing the population
by quartiles of the baseline data (n 
219) or the 1-year change data (n 
163). Figure 1 presents Kaplan-Meier
analyses of progression-free survival
by quartile. Most notably, these pa-
rameters did not exhibit monotonic
relationships across quartiles. In par-
ticular, participants in the highest
quartile of weight exhibited a differ-
ent rate of progression compared to
others, and the top two quartiles of
fasting glucose behaved similarly to
each other but differed from each of
the lower two quartiles. In terms of
the effects of change parameters,
again the relationships were not
monotonic, and in particular those
who failed to reduce fasting glucose
progressed more rapidly than those
who maintained or reduced their
fasting glucose. Survival-free pro-
gression differed by quartiles of in-
sulin resistance (inverse fasting insu-
lin, borderline significant atP .03),
but there was no difference in pro-
gression by quartile of -cell func-
tion (oral disposition index, P 
.14), change in insulin resistance
(P  .44), or change in -cell func-
tion (P  .73; data not shown).
The determinants of progression
were evaluated using Cox propor-
tional hazards modeling (Table 3).
Initial analyses determined that age was related to pro-
gression status, but sex and race were not related to pro-
gression status or the metabolic parameters evaluated;
therefore the models were age-adjusted. Analyses were
performed in a planned stepwise manner. First, all indi-
vidual parameters of interest were evaluated as adjusted
univariate relationships. Next, a multivariable model was
built using baseline parameters that met inclusion criteria
as univariate terms (P  .20). Next was a similar model
also incorporating parameters for 1-year change that met
criteria for inclusion. Finally, a parallel model was built
incorporating baseline plus time-dependent change pa-
rameters, incorporating all available data out to 5 years of
observation. Parameters that were strongly associated
Figure 1. Progression-free survival presented by quartiles of variables of interest. The P value
represents the Cox proportional hazards comparison across the four quartiles of each parameter.
Quartiles are numbered from 1 (lowest) to 4 (highest); cut-points for these quartiles are
presented on each figure. 2hG, 2-hour glucose on the OGTT.
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with progression status in univariate analyses included
baseline fasting glucose and year-1 change in fasting glu-
cose, change in2-hourOGTTglucose, andbaselinenones-
terified fatty acid concentrations. Weight, change in
weight, lipid concentrations, and measures of insulin re-
sistanceand-cell functionwereofborderline significance
or were not associated with progression by univariate
analysis. The multivariable models identified persisting
independent highly significant effects only of baseline and
change in fasting glucose concentrations (producing par-
allel results with evaluations using year-1 change and
time-dependent change).
The overall 1-year change in fasting glucose was a low-
ering of glucose (ie, a negative value), and as is evident in
Figure 1, the risk of progression was lowest among those
with the greatest reductions in fasting glucose. We there-
fore undertook analyses to better explain this effect. These
are shown in Table 4, which presents a set of linear re-
gression analyses using the 1-year change in FPG as the
dependent variable. In parallel with the approach applied
for the Cox modeling, univariate regressions against pa-
rameters of interest were first evaluated, followed bymul-
tivariable relationships with baseline variables, and then
multivariable relationships with baseline and 1-year
change variables. Age, sex, and race were not individually
associated with the 1-year change in fasting glucose, and
including them as adjustments in the univariate associa-
tions did not materially alter the other relationships (data
not shown); therefore the unadjusted relationships are
presented (Table 4). In contrast to the main study result,
which found no treatment differences evaluating the
change in fasting glucose collected over 5 years of obser-
vation (1), the 1-year change in fasting glucosewas greater
among those randomized to acarbose, but of borderline
significance. The baseline fasting glucose (highly signifi-
cant) andbaselineHDL/TG ratio (borderline significance)
were univariate determinants of change in fasting glucose,
both inversely related. The 1-year change in weight and
the change in 2-hour OGTT glucose were very strongly
associated with the change in fasting glucose, and a less
potent effect of borderline significance was also seen with
a change in the HDL/TG ratio. These relationships were
direct, ie, reductions in fasting glucose were seen in asso-
ciation with reductions in these parameters. In the multi-
variable analyses, after controlling for the effect of base-
line fasting glucose and HDL/TG ratio, the changes in
weight and 2-hour OGTT glucose retained significance.
The acarbose effect did not remain significant after in-
cluding changes in weight, 2-hour glucose, and HDL/TG
ratio. Study medication adherence was high (90% at
year 1) and was not different between treatment groups;
adherence was not related to change in fasting glucose
(data not shown).
Figure 2presents the primarydeterminants of change in
fasting glucose graphically, revealing some nonlinearity in
the relationships. Noteworthy features include the greater
Table 3. Cox Proportional Hazard Analyses Evaluating Association of Baseline, Year 1 Change, and Overall Time-
Dependent Change in Metabolic Variables With Progression of Fasting Glucose
Variables
Univariate
Multivariable Baseline
Multivariable Baseline 
Year 1 Change
Multivariable
Baseline  TDC
2 49, P  2.17  108 2 84, P  2.58  1014 2 128, P  4.00  1022
Parameter Estimate
(1 y  TDC)
P Value
(1 y  TDC)
Parameter
Estimate P Value
Parameter
Estimate P Value
Parameter
Estimate P Value
Acarbose vs Placebo 0.192 .45
Weight, kg 0.012 .027 0.003 .72 0.000 .80 0.003 .75
	Weight, kg 0.030  0.059 .21  .02 0.049 .25
FPG, mmol/L 0.004 7.80 
 108 0.004 3.62 
 107 0.005 1.44 
 109 0.007 3.17 
 1010
	 FPG, mmol/L 0.002  0.004 4.78 
 104  1.15 
 1013 0.003 4.70 
 105 0.005 2.32 
 109
OGTT glucose at 120 min, mmol/L 0.0003 .09 0.0002 .28 0.0004 .17 0.0002 .52
	 OGTT glucose (120 min), mmol/L 0.0004  0.0007 .019  1.0 
 106 0.0001 .67 0.0006 .74
HDL/TG ratio 0.89 .037 0.88 .04 0.40 .43 0.62 .23
	 HDL/TG ratio 0.37  0.74 .36  .046 0.50 .37
Fasting NEFA, mmol/L 0.001 .15 0.001 .23 0.001 .50 0.000 .79
	 Fasting NEFA, mmol/L 0.000  0.000 .70  .63
1/Fasting insulin, pmol/L 5.54 .10 15.54 .41 12.35 .56 0.006 .74
	 1/Fasting insulin, pmol/L 1.21  3.09 .38  .77
Disposition index, U 0.002 .89
	 Disposition index, U 0.002  0.004 .85  .76
Abbreviation: NEFA, non-esterified fatty acids. Note: Cox proportional hazards analyses for determinants of progression status are shown. Age-
adjusted multivariable analyses are presented. The multivariable models include terms that were associated with progression with P  .20 in
univariate analyses except parameters of insulin resistance and -cell function, which were forced into the models (see Subjects and Methods).
Change variables (	) were included as 1-year change after randomization or as TDC after randomization.  indicates that parallel testing was done
using parameters at 1 year and all available data as time-dependent change. The time-dependent covariate parameters include all available data
over the course of observation; for NEFA, these data were available only to year 2, whereas for other parameters these data were available to year
5 after randomization. The parameter estimates represent the strength of association per unit of the independent variable, with positive values
representing a direct association and negative values representing an inverse association.
4080 Patel et al Determinants of Early Diabetes Progression J Clin Endocrinol Metab, November 2016, 101(11):4076–4084
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/101/11/4076/2764951 by Bernetta Evans user on 14 August 2019
reductions observed among those with higher baseline
FPG; the observation that the HDL/TG ratio relationship
appears to be dominated by a modest population-wide
reduction in this ratio rather than a quartile-dependent
relationship; an evident threshold effect for reduction in
weight as a determinant of reductions in fasting glucose;
and a similar effect with 120-minute glucose, where only
those with the greatest reductions in 120-minute glucose
showed reductions in fasting glucose.
These results demonstrate an important beneficial
effect of weight loss and accompanying reductions in
glucose and lipids as factors underlying the prevention
of a worsening of fasting glucose in this early diabetes
population.
Discussion
Herewe have demonstrated that in the EDIP, the on-study
reduction in fasting glucose was strongly associated with
protection from progression (defined in the EDIP as
achieving a fasting glucose 140mg/dL, or 7.8 mmol/L).
This effect was seen after adjustment for the baseline fasting
glucose and is therefore not simply an effect of reducing
glucose values in those closest to the threshold; rather, it
represents the integrated beneficial effect of study interven-
tions. The change in fasting glucose was in turn strongly
and directly related to reductions in weight and reductions
in 2-hourOGTT glucose. Notably, we observed a threshold
effect for weight loss, where approximately 5–6% weight
losswasmost reliably associatedwith improvements in fast-
ing glucose. These changes took place despite the baseline
states of fasting hyperglycemia, poor -cell function, and a
lack of improvement in -cell function that we have pre-
viously reported (2). Treatment with acarbose was asso-
ciated with greater reductions in fasting glucose, but this
effect was of borderline significance and was weaker than
the potent overall roles of weight reduction and lowering
of 2-hour glucose values, effects that were not unique to
the acarbose treatment. The concurrent increases in the
HDL/TG ratio point to underlying changes in diet and
weight as drivers of the observed changes. These obser-
vations argue that study participation conferred these ef-
fects independent of randomized study medications,
which suggests that the study-wide dietary recommenda-
tions, along with the nonspecific beneficial effects of par-
ticipation in a clinical trial, contributed to these results.
The magnitude of weight loss associated with these gly-
cemic benefits was smaller than that promoted in the Di-
abetes Prevention Program (4) and the Look AHEAD
study (5) and was achieved with a less intensive interven-
tion closer to what is possible in a usual care setting. The
current observations provide a positive message that cli-
nicians can use in implementing and motivating modest
dietary weight loss as a component of diabetes care and
prevention of metabolic worsening in early diabetes.
In the EDIP, baseline fasting glucose was a strong de-
terminant of progression of dysglycemia, an observation
that hasbeenwidely reported in epidemiological studies of
Table 4. Determinants of Year 1 Change in FPG
Baseline Variables
Univariate
Multivariable Baseline,
R2  0.15, P  2 
 106
Multivariable
Baseline  Change,
R2 0.34, P 3
 109
Parameter
Estimate PValue
Parameter
Estimate PValue
Parameter
Estimate PValue
Acarbose vs placebo 0.165 .034 0.144 .048 0.063 .41
Weight, kg 0.071 .36
	Weight, kg 0.55 2.4 
 1014 0.264 .003
FPG, mmol/L 0.335 1.1 
 105 0.334 8.0 
 106 0.174 .025
OGTT glucose at 120 min, mmol/L 0.091 .24
	 OGTT glucose (120 min), mmol/L 0.534 2.2 
 1013 0.315 .001
HDL/TG ratio 0.168 .031 0.17 .019 0.163 .044
	 HDL/TG ratio 0.159 .050 0.097 .23
Fasting NEFA, mmol/L 0.014 .86
	 Fasting NEFA, mmol/L 0.095 .23
1/Fasting insulin, pmol/L 0.024 .77
	 1/Fasting insulin, pmol/L 0.09 .30
Disposition index, U 0.052 .53
	 Disposition index, U 0.138 .13 0.085 .27
Abbreviation: NEFA, non-esterified fatty acids. Note: Generalized linear model analyses for determinants of change in fasting glucose from baseline
to year 1 are shown. The multivariable models include terms that were associated with progression with P  .20 in univariate analyses, with no
terms forced into the modeling. The parsimonious model includes only terms individually significant at P  .05 in the prior model. The parameter
estimates represent the strength of association per unit of the independent variable, with positive values representing a direct association and
negative values representing an inverse association.
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progression of dysglycemia (6–10) and studies of diabetes
treatments and their effects on diabetes progression (11–
15). Under the definition of progression used in the EDIP,
this relationship can be seen as tautological, with initial
glucose values closer to the threshold predisposing indi-
viduals to crossing the fixed threshold defining progres-
sion. This problem of logic also applies to other studies of
diabetes progression that apply diagnostic cut-points as
endpoints. However, we also observed that baseline glu-
cose was inversely associated with the protective reduc-
tions in fasting glucose (Table 4), such that those with the
highest baseline glucose values exhibited the largest on-
study reductions in glucose (Figure 2). This effect did not
remove the strong predictive effect of fasting glucose, sug-
gesting that dual effects are in play, with an elevated glu-
cose reflecting a more adverse overall risk status but also
a greater opportunity for improvement in glucose, with its
attendant benefits. Although participants were newly di-
agnosed with diabetes based on a screening OGTT at the
time of study entry, it is possible that different durations
and rates of change of dysglycemia before diagnosis sep-
arate those who progress vs those who do not, and that
these tendencies manifest as the observed differences in
absolute fasting glucose and differences in rate of change
starting from the start of observation while on study.
It is perhaps paradoxical that the ac-
arbose intervention was effective in
lowering fasting glycemia (Table 4) but
was not effective in preventing overall
5-year progression (1). The underlying
premise of the trial was that targeting
postprandial hyperglycemia with acar-
bose would mitigate the glucose excur-
sion-related risk of progression of early
diabetes. The mechanism(s) underlying
thecontributionofhyperglycemia topro-
gressive glycemic dysregulation are in-
completely understood but are likely re-
lated tooxidant load,withadverse effects
on -cells (16) and on peripheral insulin
responses (17). If we assume that this
toxic effect of hyperglycemia is reversible
(an assumptionwith reasonable support)
(18), the lackofbenefitofaneffectiveglu-
cose-lowering therapy can be interpreted
either as an insufficient potency of glu-
cose lowering for this stage of disease or
as concurrent progression despite effec-
tive therapy. These observations are
consistent with a more advanced state
of underlying metabolic dysfunction
among the progressors, where the over-
all glucose-lowering effect of acarbose was insufficient to
mitigate the overall glucose toxicity arising from fasting
and/or post-OGTT hyperglycemia. Data from the current
study do not allow us to comment on other physiological
factors that might contribute to progressive loss of meta-
bolic control, but these data are consistent with an im-
portant direct effect of hyperglycemia on progressive loss
of glycemic control and a protective effect of reduction in
glycemia. It is not currently known whether other inter-
ventions to reduce glycemia, differing in mechanism of
glucose lowering, in magnitude of glucose reductions and
in reductions of fasting vs prandial glucose excursions,
will exert differential effects to mitigate progressive dys-
glycemia in early diabetes. The current model of diabetes
progression suggests that after reaching the stage of im-
paired glucose tolerance, progressive loss of -cell func-
tion becomes the dominant factor in the progression of
loss of glycemic control (7, 19–25). Insulin resistance is
generally understood to be a necessary background state,
with improvements in insulin resistance aiding glycemic
control by allowing overall better glucose management
with existing levels of -cell function (7, 19–21, 26). Our
population exhibited a reasonable range of physiological
parameters of interest for these components of metabolic
physiology, including HOMA-IR and disposition index
Figure 2. Determinants of 1-year change in FPG, presented by quartile. The upper, middle, and
lower boundaries of the boxes represent the 75th, 50th, and 25th percentiles for each quartile;
the outermost lines are at the 95th and fifth percentiles and data points beyond these limits are
individually shown. Significance values are presented for the comparison of change in FPG by
quartile.
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(Table 1). Our data are in contrast with the expectation
that treatment effectsmight bemediatedby improvements
in insulin resistance and/or -cell function.We found that
progressors and non-progressors did not differ at baseline
on these features (Table 2). Despite on-study reductions in
weight and improvements in the HDL/TG ratio,
HOMA-IR was not different after 1 year of study inter-
vention, and progression groups did not differ in this fea-
ture. The disposition index was significantly reduced
(worse) after 1 year of study intervention, an effect that
was not different between groups. In this context, it is not
surprising that neither insulin resistance nor -cell func-
tion was individually related to the risk of progression.
These observations do not rebut the prior literature link-
ing the beneficial effects of treatments targeting insulin
resistance or -cell function, and it seems likely that the
relevant factors that determined differences in the rates of
progression were unmeasured factors for which weight
loss is a marker, such as inflammation, cytokine stress,
immune activation, and other putative pathophysiologi-
cal factors (27).Nevertheless, these observations highlight
the possibility that treatments that achieveweight loss and
glucose reductions can producemetabolic benefits even in
the absence of beneficial effects on insulin resistance and
-cell function.
Limitations
A clinical trial population is defined by the needs of a
particular study question, which can limit generalizability
and produce a limited range of values for parameters that
are affected by inclusion criteria. It is possible that this
effect may have limited our ability to demonstrate contri-
butions of insulin resistance or -cell function to the pro-
gressionof fastingglucose.Also, the currentlydefined sub-
groups may differ in one or more unmeasured factors that
importantly influenced the outcomes evaluated here, al-
though it seems unlikely that such factors dominate the
currently observed highly significant effects. The statisti-
cal threshold applied in these exploratory analyses could
be insufficiently rigorous to exclude false-positive obser-
vations; nevertheless, the major findings presented here
achieved very high degrees of statistical significance, and
we have been careful not to overinterpret observations
with borderline significance. Due to the study design, we
have no data on participants after they met criteria for
progression, which limits analyses to events before the
progression event. It would be of interest in subsequent
studies to consider ongoing progression after individuals
cross study-defined or diagnostic thresholds.
Conclusions
In a population with early, screen-detected diabetes,
reductions in glucose, driven by reductions in weight, can
delay progressive metabolic worsening. These observa-
tions underscore the importance of lifestyle management
includingweight loss as a tool tomitigate theworsening of
glycemia in newly diagnosed diabetes.
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